Research programme: prodrug therapeutics - Ascendis Pharma

Drug Profile

Research programme: prodrug therapeutics - Ascendis Pharma

Alternative Names: TransCon Hydrogel GLP-1; TransCon Hydrogel insulin; TransCon Hydrogel paliperidone; TransCon Hydrogel pramipexole; TransCon PEG interferon α

Latest Information Update: 02 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ascendis Pharma
  • Class Benzothiazoles; Glucagon-like peptides; Insulins; Interferons; Isoxazoles; Polyethylene glycols
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists; Dopamine D3 receptor agonists; Dopamine D4 receptor agonists; Glucagon like peptide 1 receptor agonists; Insulin receptor agonists; Interferon alpha stimulants; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical CNS disorders; Diabetes mellitus; Hepatitis C

Most Recent Events

  • 08 Jan 2018 Ascendis Pharma plans a first-in-human phase I trial for TransCon CNP in Achondroplasia (In volunteers) in Australia in the second quarter of 2018
  • 03 Apr 2017 Ascendis Pharma plans a phase I trial for Hypoparathyroidism in 2017
  • 31 Aug 2016 Ascendis announces intention to submit IND application to the US FDA in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top